The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Infectious complications in SLE after immunosuppressive therapies
Abstract
Immunosuppressive drugs have become the gold standard for the treatment of major organ involvement in systemic lupus erythematosus. The use of immunosuppressive therapy in systemic lupus erythematosus carries significant risks for infection. This article reviews infectious complications in systemic lupus erythematosus, focusing on effects of immunosuppressive therapy. Patients with systemic lupus erythematosus appear to carry an intrinsically increased risk for infection. Recent studies support this notion further by showing increased risk for serious infections in patients with systemic lupus erythematosus who had mannose-binding lectin deficiency associated with homozygous mannose-binding lectin variant alleles. Patients with systemic lupus erythematosus who were homozygous for mannose-binding lectin variant alleles had a fourfold increase in the incidence of infections, requiring hospitalization. In terms of extrinsic risk factors for infection, use of steroids and cyclophosphamide are the strongest risk factors. The effect of these drugs on infection is also dose dependent. The incidence of infectious complications in patients treated with mycophenolate mofetil, a newly used immunosuppressive drug in systemic lupus erythematosus, appears less frequent compared with cyclophosphamide. Herpes zoster is still the most common viral infection in patients with systemic lupus erythematosus treated with cyclophosphamide and mycophenolate mofetil. Overall data indicate that patients with systemic lupus erythematosus may have intrinsically increased risks for infection that are augmented by immunosuppressive therapies. Cyclophosphamide, in particular in combination with high-dose glucocorticoids, has the strongest effect in suppressing the immune responses against microorganisms. Careful monitoring of infectious complications is warranted in patients with systemic lupus erythematosus receiving immunosuppressive therapies, in particular those on high-dose glucocorticoids and cytotoxic drugs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Austin, H. A., Klippel, J. H., Balow, J. E., Le Riche, N. G. H., Steinberg, A. D., Plotz, P. H., & Decker, J. L. (1986) · New England Journal of Medicine · doi:10.1056/nejm198603063141004 · Cited by 1,185
Houssiau, F. A., Vasconcelos, C., D'Cruz, D., Sebastiani, G. D., Garrido, E. D. R., Danieli, M. G., Abramovicz, D., Blockmans, D., Mathieu, A., Direskeneli, H., et al. (2002) · Arthritis & Rheumatism · doi:10.1002/art.10461 · Cited by 1,077
Glucocorticosteroid Therapy: Mechanisms of Action and Clinical Considerations
FAUCI, A. S., DALE, D. C., & BALOW, J. E. (1976) · Annals of Internal Medicine · doi:10.7326/0003-4819-84-3-304 · Cited by 1,044
Glucocorticoid Therapy for Immune-Mediated Diseases: Basic and Clinical Correlates
Boumpas, D. T., Chrousos, G. P., Wilder, R. L., Cupps, T. R., & Balow, J. E. (1993) · Annals of Internal Medicine · doi:10.7326/0003-4819-119-12-199312150-00007 · Cited by 778
Gourley, M. F., Austin III, H. A., Scott, D., Yarboro, C. H., Vaughan, E. M., Muir, J., Boumpas, D. T., Klippel, J. H., Balow, J. E., & Steinberg, A. D. (1996) · Annals of Internal Medicine · doi:10.7326/0003-4819-125-7-199610010-00003 · Cited by 607
Illei, G. G., Austin, H. A., Crane, M., Collins, L., Gourley, M. F., Yarboro, C. H., Vaughan, E. M., Kuroiwa, T., Danning, C. L., Steinberg, A. D., et al. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-135-4-200108210-00009 · Cited by 492
Cervera, R., Khamashta, M. A., Font, J., Sebastiani, G. D., Gil, A., Lavilla, P., Aydintug, A. O., Jedryka-Góral, A., Ramón, E. D., Fernández-Nebro, A., et al. (1999) · Medicine · doi:10.1097/00005792-199905000-00003 · Cited by 430
Computer analysis of factors influencing frequency of infection in systemic lupus erythematosus
Ginzler, E., Diamond, H., Kaplan, D., Weiner, M., Schlesinger, M., & Seleznick, M. (1978) · Arthritis & Rheumatism · doi:10.1002/art.1780210107 · Cited by 281
Incidence of infection in systemic lupus erythematosus
Staples, P. J., Gerding, D. N., Decker, J. L., & Gordon, R. S. (1974) · Arthritis & Rheumatism · doi:10.1002/art.1780170102 · Cited by 269
Traynor, A. E., Schroeder, J., Rosa, R. M., Cheng, D., Stefka, J., Mujais, S., Baker, S., & Burt, R. K. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02627-1 · Cited by 245
Cited by
Long-Term Prognosis and Causes of Death in Systemic Lupus Erythematosus
Doria, A., Iaccarino, L., Ghirardello, A., Zampieri, S., Arienti, S., Sarzi-Puttini, P., Atzeni, F., Piccoli, A., & Todesco, S. (2006) · The American Journal of Medicine · doi:10.1016/j.amjmed.2005.11.034 · Cited by 350
He, J., Zhang, R., Shao, M., Zhao, X., Miao, M., Chen, J., Liu, J., Zhang, X., Zhang, X., Jin, Y., et al. (2020) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2019-215396 · Cited by 345
Nonmyeloablative Hematopoietic Stem Cell Transplantation for Systemic Lupus Erythematosus
Burt, R. K. (2006) · JAMA · doi:10.1001/jama.295.5.527 · Cited by 290
Zandman-Goddard, G., Shoenfeld, Y., Zandman-Goddard, G., & Shoenfeld, Y. (2005) · Autoimmunity · doi:10.1080/08916930500285352 · Cited by 284
Defective Control of Latent Epstein-Barr Virus Infection in Systemic Lupus Erythematosus
Kang, I., Quan, T., Nolasco, H., Park, S.-H., Hong, M. S., Crouch, J., Pamer, E. G., Howe, J. G., & Craft, J. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.2.1287 · Cited by 275
Self-citation
Metadata
- Authors
- Kang, I., & Park, S. H.
- Venue
- Current Opinion in Rheumatology
- Published
- 2003-09
- Volume
- 15
- Issue
- 5
- Pages
- 528-534
- ISSN
- 1040-8711 (ISSN-L)
- OpenAlex
- W1981610922
- Cited by
- 255
- References
- 41
- FWCI
- 5.75
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Infectious complications in SLE after immunosuppressive therapies. https://app.cochat.ai/papers/10.1097/00002281-200309000-00002
- The paper
- Kang, I., & Park, S. H. (2003). Infectious complications in SLE after immunosuppressive therapies. Current Opinion in Rheumatology. https://doi.org/10.1097/00002281-200309000-00002
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.